Results 71 to 80 of about 114,754,979 (236)

Impact of Frailty on Surgical Outcomes in Patients Treated for Cricopharyngeus Muscle Dysfunction

The Laryngoscope, EarlyView.
ABSTRACT Objective To investigate the relationship between frailty status and surgical outcomes in patients undergoing procedures for cricopharyngeus muscle dysfunction (CPMD). Methods Retrospective chart review of all patients who underwent upper esophageal sphincter (UES) interventions at a tertiary dysphagia center.
Jessa Letargo, Ramey Kharfan, Charmaine Szalay‐Anderson, Derrick R. Randall   +3 more
wiley   +1 more source

Variability of Botulinum Toxins: Challenges and Opportunities for the Future

, 2018
Botulinum neurotoxins (BoNTs) are the most potent known toxins, and are therefore classified as extremely harmful biological weapons. However, BoNTs are therapeutic drugs that are widely used and have an increasing number of applications.
Rasetti-Escargueil, Christine, Michel R. Popoff, Popoff, Michel,, Popoff, Michel, R., Christine Rasetti-Escargueil, Emmanuel Lemichez, Lemichez, Emmanuel, Michel R. Popoff   +7 more
core   +1 more source

Safety and Efficacy of 10 kHz Spinal Cord Stimulation for the Treatment of Refractory Chronic Migraine: A Prospective Long‐Term Open‐Label Study

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Background Refractory chronic migraine (rCM) is a highly disabling condition for which novel safe and effective treatments are needed. Safety and long‐term efficacy of paresthesia‐free high cervical 10 kHz spinal cord stimulation (SCS) were here prospectively evaluated for the treatment of rCM.
Adnan Al‐Kaisy, Stefano Palmisani, Roy Carganillo, Samuel Wesley, David Pang, Anand Rotte, Angela Santos, Giorgio Lambru   +7 more
wiley   +1 more source

Mechanisms of Botulinum Toxin Type A Action on Pain [PDF]

Toxins, 2019
Already a well-established treatment for different autonomic and movement disorders, the use of botulinum toxin type A (BoNT/A) in pain conditions is now continuously expanding. Currently, the only approved use of BoNT/A in relation to pain is the treatment of chronic migraines. However, controlled clinical studies show promising results in neuropathic
Matak, Ivica, Bölcskei, Kata, Bach-Rojecky, Lidija, Helyes, Zsuzsanna   +3 more
openaire   +6 more sources

Report of Adverse Events Associated With Cutaneous Procedures: Update From the CAPER Registry

Lasers in Surgery and Medicine, EarlyView.
ABSTRACT Objectives To systematically evaluate submissions to the CAPER database by analyzing procedural context, characteristics of reported adverse events (AEs), and provider involvement in order to identify patterns with potential implications for patient safety.
Sabrina S. Smith, Michael D. Yi, Elizabeth Zhang, Joycie Chang, Thanvi Gullapalli, Doroteja Dragovic, Vanessa J. Lazaro‐Camp, Ashish C. Bhatia, Arisa Ortiz, Murad Alam   +9 more
wiley   +1 more source

The role of the host—Neutrophil biology

Periodontology 2000, EarlyView., 2023
Abstract Neutrophilic polymorphonuclear leukocytes (neutrophils) are myeloid cells packed with lysosomal granules (hence also called granulocytes) that contain a formidable antimicrobial arsenal. They are terminally differentiated cells that play a critical role in acute and chronic inflammation, as well as in the resolution of inflammation and wound ...
Iain L. C. Chapple, Josefine Hirschfeld, Alpdogan Kantarci, Asaf Wilensky, Lior Shapira   +4 more
wiley   +1 more source

Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications

, 2021
Over the last few decades, proteins and peptides have become increasingly more common as FDA-approved drugs, despite their inefficient delivery due to their inability to cross the plasma membrane.
Oksana A. Sergeeva, F. Gisou van der Goot, Numa Piot   +2 more
core   +1 more source

Real‐World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9‐Year Nationwide Analysis in France

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Hyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT‐A). Real‐world evidence on treatment patterns remains limited. Objective This nationwide, population‐based study aimed to evaluate trends in BoNT‐A use in France between 2015 and 2023 ...
Marion Simonetta‐Moreau, Pierre Karam, Anne Forestier, Bertrand Degos   +3 more
wiley   +1 more source

Bacterial Toxins: Friends or Foes?

Emerging Infectious Diseases, 1999
Many emerging and reemerging bacterial pathogens synthesize toxins that serve as primary virulence factors. We highlight seven bacterial toxins produced by well-established or newly emergent pathogenic microbes.
Clare K. Schmitt, Karen C. Meysick, Alison D. O'Brien   +2 more
doaj   +1 more source

From Disability to Diagnosis: Baseline Findings from the Calgary Functional Movement Disorder Registry

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Functional movement disorder (FMD), a subtype of functional neurological disorder, is a complex neuropsychiatric syndrome characterized by inconsistent and incongruent motor symptoms. Despite its relatively high prevalence, FMD remains associated with delayed diagnosis, significant disability, and limited evidence to guide ...
Andrea Soumbasis, Brian Steele, Megan Howlett, Kate Kain, Davide Martino, Kimberly G. Williams, Gabriela S. Gilmour   +6 more
wiley   +1 more source